4 completed, 1 withdrawn. 3 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 4 | 1 | Completed 1 |
Follow Transfusional Hemosiderosis: new trials by email Literature Review of Transfusional Hemosiderosis trials Research Report on Transfusional Hemosiderosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Iron Overload Requiring Chelation Therapy SPD602, Deferasirox - Transfusional Iron Overload, Iron Overload | Phase 2 | Withdrawn | Shire | 2014-11-20 | 2021-06-02 | |
| Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox deferasirox - Transfusional Hemosiderosis | Completed | Novartis Pharmaceuticals | 120 | 2011-07-01 | 2016-02-02 | |
| Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food deferasirox: - Transfusional Hemosiderosis | Phase 4 | Completed | Novartis Pharmaceuticals | 65 | 2009-05-01 | 2021-07-20 |
| Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload Core Study: Deferasirox, Core Study: Deferoxamine, Extension: deferoxamine to deferasirox - Transfusional Iron Overload, Transfusional Hemosiderosis | Phase 2 | Completed | Novartis Pharmaceuticals | 197 | 2007-11-01 | 2014-08-27 |
| Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis Deferasirox (ICL670) - Chronic Anemia, Transfusional Hemosiderosis | Phase 2 | Completed | Novartis Pharmaceuticals | 102 | 2007-10-01 | 2021-06-29 |
Iron Overload (5) · Anemia, Diamond-Blackfan (1) · Anemia, Sideroblastic (1) · Hemochromatosis (1) · Iron Metabolism Disorders (1) · Metabolic Diseases (1) · Myelodysplastic Syndromes (1) · Thalassemia (1) · beta-Thalassemia (1)
Nutritional and Metabolic Diseases (5) · Iron Metabolism Disorders (4) · Metabolic Diseases (4) · Anemia (2) · Anemia, Hemolytic (2) · Anemia, Hemolytic, Congenital (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemoglobinopathies (2) · Anemia, Aplastic (1) · Anemia, Hypoplastic, Congenital (1) · Bone Marrow Diseases (1) · Bone Marrow Failure Disorders (1)
Deferasirox (5) · Deferoxamine (1)
Novartis Pharmaceuticals (4) · Shire (1)
Egypt (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Canada (1) · China (1) · Cyprus (1) · Italy (1) · Japan (1) · Jordan (1) · Lebanon (1) · Poland (1) · Singapore (1) · Taiwan (1) · Thailand (1)
PMID 23637051, PMID 24385534, PMID 25345697, PMID 26138856, PMID 37975597